OrthoAccel Technologies Inc, Houston, has received an investment of $10 million in growth capital to fund the US launch of its AcceleDent™ system and ongoing working capital needs. The investment was led by HealthpointCapital Partners, with existing investor S3 Ventures also participating. In conjunction with the financing, HealthpointCapital’s John McCormick will join the company’s board of directors, and Brian R. Smith from S3 Ventures will remain on the board.

"OrthoAccel represents a rare opportunity to invest in a company positioned to change an industry," said John McCormick, managing director at HealthpointCapital. "OrthoAccel’s AcceleDent system gives patients an unprecedented option to substantially reduce their orthodontic treatment time through a simple, 20-minute, daily-use process."

AcceleDent has been introduced to the United Kingdom, Australia, France, Italy, and approximately a dozen other countries since 2012. In November 2011, OrthoAccel received FDA 510(k) approval to sell in the United States following a successful prospective, randomized, blinded clinical trial. The AcceleDent system made its American debut at the AAO Annual Session in Honolulu.

For more information about this and other orthodontic companies, visit our Buyer’s Guide.